NASD · Healthcare · Biotechnology · USA
Scholar Rock Holding Corp is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Scholar Rock Holding Corp is a global biopharmaceutical company developing monoclonal antibodies to treat spinal muscular atrophy and rare neuromuscular diseases. The company's proprietary platform targets latent forms of growth factors, with apitegromab as its lead candidate for treating children and adults with SMA and facioscapulohumeral muscular dystrophy.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Scholar Rock Holding Corp stock.
Overvalued: intrinsic value $1.85 per share, market price $45.08, margin of safety -2342.6% (as of 2026-11-17).
A 2.4x revenue multiple, discounted for its losses, values the shares at $1.85; the price of $45.08 is 2343% above that value.
17 more funds hold it; the full list is part of the paid plan.
117 more in this industry show a wider margin of safety.
SRRK is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $1.85; the price of $45.08 is 2343% above that value.
$1.85 per share (as of the 2026-11-17 close), against a market price of $45.08. That is a margin of safety of -2342.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.